Difference between revisions of "Dabrafenib (Tafinlar)"
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
Line 26: | Line 26: | ||
===[[Thyroid cancer]]=== | ===[[Thyroid cancer]]=== | ||
*5/4/2018: FDA approval with [[Trametinib (Mekinist)]] in combination for the treatment of patients with locally advanced or metastatic [[Thyroid_cancer|anaplastic thyroid cancer (ATC)]] with [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E mutation]] and with no satisfactory locoregional treatment options. ''(Based on BRF117019)'' | *5/4/2018: FDA approval with [[Trametinib (Mekinist)]] in combination for the treatment of patients with locally advanced or metastatic [[Thyroid_cancer|anaplastic thyroid cancer (ATC)]] with [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E mutation]] and with no satisfactory locoregional treatment options. ''(Based on BRF117019)'' | ||
+ | |||
+ | ==History of changes in EMA indication== | ||
+ | *8/26/2013: Initial marketing authorization as Tafinlar. | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' GSK2118436, GSK-2118436A | *'''Code names:''' GSK2118436, GSK-2118436A | ||
*'''Generic name:''' dabrafenib mesylate | *'''Generic name:''' dabrafenib mesylate | ||
− | *'''Brand name:''' Tafinlar | + | *'''Brand name:''' Rafinlar, Tafinlar |
==References== | ==References== | ||
Line 47: | Line 50: | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
+ | [[Category:EMA approved in 2013]] | ||
[[Category:FDA approved in 2013]] | [[Category:FDA approved in 2013]] |
Revision as of 01:53, 5 December 2021
General information
Class/mechanism: BRAF kinase inhibitor. Dabrafenib inhibits some mutated BRAF kinases, such as BRAF V600E, BRAF V600K, and BRAF V600D. Some BRAF mutations such as BRAF V600E cause constitutive activation of the BRAF pathway, which drives tumor cell growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- BRAF-mutated melanoma
- BRAF-mutated NSCLC
- BRAF-mutated anaplastic thyroid cancer
- BRAF-mutated tumors (disease-agnostic)
Patient drug information
History of changes in FDA indication
Melanoma
- 5/29/2013: FDA approved for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. (Based on BREAK-3 and BREAK-MB)
- 1/10/2014: FDA approved to be used together with Trametinib (Mekinist) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. (Based on COMBI-d, COMBI-v, and COMBI-MB)
- 4/30/2018: Regular FDA approval with Trametinib (Mekinist) in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. (Based on COMBI-AD)
Non-small cell lung cancer
- 6/22/2017: FDA approved in combination with Trametinib (Mekinist) for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. (Based on BRF113928)
Thyroid cancer
- 5/4/2018: FDA approval with Trametinib (Mekinist) in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. (Based on BRF117019)
History of changes in EMA indication
- 8/26/2013: Initial marketing authorization as Tafinlar.
Also known as
- Code names: GSK2118436, GSK-2118436A
- Generic name: dabrafenib mesylate
- Brand name: Rafinlar, Tafinlar